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Cells in the hyperosmotic kidney medulla, express a
transcriptional activator termed tonicity responsive enhancer
binding protein (TonEBP). Genes targeted by TonEBP protect
kidney cells from the deleterious effects of hyperosmolality
by inducing the expression of organic osmolytes and
molecular chaperones, and other genes that mediate urine
concentration such as aquaporin-2 and urea transporters. We
tested here the effect of hypertonicity and hyperosmotic salt
in the renal medullary interstitium on the expression TonEBP.
When massive water diuresis was induced in rats the
medullary sodium concentrations did not change, neither did
TonEBP expression. In these animals the medullary tonicity
was unchanged despite the production of dilute urine. On
the other hand, treatment with the loop diurectic furosemide
resulted in a dose-dependent decrease in the medullary
sodium concentration causing a reduction in interstitial
tonicity. Here, TonEBP expression was blunted in the outer
and inner medulla which was due, in part, to decreased
mRNA abundance. As expected, the expression of TonEBP
target genes in the renal medulla also decreased in response
to furosemide. Hence TonEBP expression in the renal medulla
is stimulated by interstitial hypertonicity.
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The renal medulla is the only tissue in mammals that is
hypertonic under normal, physiological conditions due to the
hyperosmotic salinity of the interstitial fluid. The tonicity of
the interstitium increases gradually from the border of the
cortex and outer medulla down to the tip of the papilla, as
does the concentration of urea. At the tip of the renal papilla,
the interstitial fluid typically contains 800 mosmol/kg of salt
and 900 mosmol/kg of urea in kidneys of euhydrated rats.1
Although the urea concentration fluctuates widely between
antidiuresis and water diuresis, the degree of salinity varies in
much smaller extents. As such, the cells in the renal medulla
are constantly bathed in variable but hypertonic fluid. Recent
studies have revealed that the hypertonicity is an important
local signal in the renal medulla. The transcription factor
tonicity-responsive enhancer binding protein (TonEBP)
appears to be a key component of the hypertonicity signaling
(reviewed in reference 2). TonEBP/ mice3 or transgenic
mice expressing a dominant negative form of TonEBP4
display profound defects in the renal medulla. First, these
animals exhibit a severe form of atrophy in the renal medulla
due to the failure of the renal cells to adapt to the stress
of hypertonicity and urea. TonEBP target genes such as
the sodium/myo-inositol cotransporter (SMIT), the Na/Cl/
betaine cotransporter, aldose reductase (AR), and recently
identified neuropathy target esterase5 encode plasma mem-
brane transporters and biosynthetic enzymes for the cellular
accumulation of organic osmolytes, which is required for
survival in hypertonicity. TonEBP also stimulates transcrip-
tion of HSP70, which protects cells from the deleterious
effects of urea. Second, the urine concentrating ability is
compromised in the animals because of reduced expressions
of AQP2 and UT-A, which are also transcriptional targets of
TonEBP.6,7
In cultured cells, TonEBP is stimulated by ambient
hypertonicity but not by hyperosmolality made by addition
of urea.2 The stimulation is associated with increased nuclear
localization, transactivation, and protein abundance.2 On the
other hand, direct evidence for the role of ambient tonicity in
regulation of TonEBP in the renal medulla has been lacking.
Water deprivation and water loading result in a nucleocyto-
plasmic shifts of TonEBP without changes in the abundance
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in the renal medulla.8 We recently reported that the
abundance of TonEBP in the renal medulla was reduced in
correlation with the downregulation of the Na-K-Cl cotran-
sporter type 2 (NKCC2) and Na,K-ATPase in response to
hypokalemia9 or long-term treatment with cyclosporine A.10
As these transporters are involved in the single effect—active
sodium reabsorption in the thick ascending limb—that drive
the accumulation of salt in the renal medullary insterstitium,
we interpret that a reduction in the interstitial salinity/
tonicity leads to reduced expression of TonEBP in the renal
medulla. In this study, we asked whether direct inhibition of
the single effect without the complications of disease
processes via administration of furosemide would lead to
downregulation of TonEBP. The results support the view that
TonEBP in the renal medulla is regulated by ambient tonicity
as in cultured cells.
RESULTS
The goal of this study was to test the hypothesis that
expression of TonEBP in the renal medulla was stimulated by
the interstitial tonicity. As rats normally displayed significant
antidiuresis with urine osmolality over 1500 mosmol/kg (see
Figure 1a), we decided to lower the renal medullary
hyperosmolality and examine TonEBP expression. Down-
regulation of TonEBP in correlation with reduced medullary
tonicity would support the hypothesis. To bring down the
renal medullary tonicity, we induced intense diuresis using
two approaches—excessive water intake (water loading) by
providing 3% sucrose solution in place of drinking water, and
continuous administration of the loop diuretic furosemide in
combination with provision of isotonic electrolyte solution to
replenish volume loss as described in Materials and Methods.
Water diuresis does not affect the renal medullary tonicity or
expression of TonEBP
Allowing rats free access to 3% sucrose solution for 3 days
resulted in a dramatic diuresis (90±5 vs 7±1 ml urine
produced per day) and dilution of urine (179±20 vs
1727±76 mosomol/kg; Figure 1a) in 3 days. Estimated
osmolality of the inner medullary tissue water (IMTW)
decreased by 26% (Po0.01; see Figure 1a) without changes
in the water content of the inner medulla (86±0.6 vs
84±0.3%, P40.05). On the other hand, estimated sodium
or potassium concentration of IMTW remained unchanged
(Figure 1a). As sodium distributed predominantly in the
interstitium of the renal medulla,11 the lack of changes in the
sodium concentration indicated that the interstitial tonicity
was not affected by the water loading. The decrease in the
osmolality of IMTW in this setting is due to the loss of
urea.12 Thus, water loading did not affect the interstitial
tonicity (or salinity) of the inner medullary interstitium
while reducing the urea concentration.
We reported previously that the activity of TonEBP in the
renal medulla, as measured by mRNA expression of its target
gene, was moderately reduced in response to water diuresis
due to cytoplasmic shift without involving changes in the
TonEBP abundance.8 In line with this, we found that
expression of TonEBP in the inner medulla was unchanged
in the water loaded animals (Figure 2, top) whereas that of
HSP70, a target of TonEBP, decreased significantly (Figure 3,
top). The lack of significant decrease in the expression of AR,
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Figure 1 | Effects of water diuresis and furosemide on urine
osmolality (Uosm), and osmolality and ion concentrations of
the inner medullary tissue water (IMTW). (a) Male rats were
allowed to free access to water (open bars) or 3% sucrose solution
(solid bars) for 3 days. Urine was collected in the last 24 h to
measure Uosm (n¼ 4). IMTW, total osmoles, Naþ , and Kþ were
measured from excised inner medullae to calculate osmolality,
[Naþ ], and [Kþ ] of IMTW (n¼ 8). Unit for osmolality is shown at
left, and unit for [Naþ ] or [Kþ ] at right. Meanþ s.e.m. @Po0.01
compared to water group. (b and c). Each animal was implanted
with an osmotic pump releasing vehicle (open bar), 12 mg
furosemide/day (striped bar), or 40 mg furosemide/day (solid bar)
for 1 day (b) or 5 days (c). Uosm (n¼ 4–6) and IMTW of inner
medullae (n¼ 8–12) were analyzed as in (a). Meanþ s.e.m.
@Po0.01 compared to vehicle, #Po0.05 compared to 12 mg
furosemide/day.
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another TonEBP target, was probably due to very long
protein half-life.13 Taken together, the data presented here
demonstrate that water diuresis did not significantly affect
the renal medullary tonicity or TonEBP expression although
the activity of TonEBP was reduced.
Effects of furosemide on plasma electrolytes and hormones
In another attempt to reduce the medullary hypertonicity, we
administered furosemide to inhibit the accumulation of salt
in the medullary interstitium. Using an osmotic minipump,
12 or 40 mg furosemide was continuously administered each
day to a male rat of B210 g body weight. Vehicle (50%
dimethyl sulfoxide) alone induced a mild diuresis as
indicated by moderate decrease in the urine osmolality
(Figure 1b and c). Furosemide administration for 1 day
resulted in dramatic increases in urine flow: 79±5 (40 mg
furosemide/day), 73±7 (12 mg furosemide/day), and
7±1 ml/day (vehicle). The urine flow increased even further
after 5 days: 223±22, 129±4, and 10±1 ml/day, respectively.
The urine flow in furosemide-treated animals was matched
precisely by the volume of the electrolyte solution ingested
(data not shown) indicating that the higher urine flow on day
5 over day 1 was driven by increased fluid intake.
Because of the high urine flow in response to furosemide
administration, we analyzed plasma samples from the
animals administered with 40 mg furosemide/day (Table 1)
to understand systemic changes in these animals. Plasma
creatinine and blood urea nitrogen increased significantly on
day 1 but returned to normal on day 5. We interpreted that
the onslaught of diuresis caused severe volume depletion, as
indicated by elevation of plasma albumin, and a dramatic
decrease in glomerular filtration rate on day 1. As the animals
learned to drink the electrolyte solution more (see above) and
replenish the volume, the glomerular filtration rate returned
to normal as indicated by normal plasma creatinine and
blood urea nitrogen on day 5. Circulating levels of
vasopressin increased on day 1 and day 5 most likely
reflecting the response to volume contraction. Aldosterone
level also increased likely reflecting increased renin release in
response to volume contraction as well as direct effect of
furosemide.14 The plasma electrolytes remained normal
except for mild hypokalemia and on day 1. Analyses of the
blood gas revealed that metabolic alkalosis marked by
elevated HCO3
 was properly compensated as the animals
did not display significant alkalemia. Overall, the plasma
electrolytes and pH were close to normal, especially on day 5,
in the animals administered with furosemide.
Downregulation of TonEBP in the renal medulla in
association with reduced interstitial tonicity in response
to furosemide treatment
In response to the two doses of furosemide, IMTW increased
significantly on day 1 (87±0.3% for both 12 and 40 mg
furosemide/day vs 85±0.5% for vehicle, Po0.01 for both
compared to vehicle) but not on day 5 (data not shown). Even
though the urine osmolality was higher in the furosemide-
treated animals compared to the water loaded animals,
osmolality and sodium concentration of IMTW were lower
(Figure 1). The reduction in the sodium concentration
indicated that the tonicity in the inner medullary interstitium
was reduced by the furosemide administration. The lack of
significant changes in potassium concentration of IMTW,
which represents the ionic strength inside the cell, is consistent
with the regulation of organic osmolytes in maintaining
constant intracelluar ionic strength.15
Osmolality of IMTW was significantly lower in animals
treated with 40 mg furosemide/day compared to those with
12 mg furosemide/day on both day 1 and day 5. Likewise,
sodium concentration of IMTW was significantly lower on
day 5, albeit by a small margin. To understand the basis for
these differences, we examined expression of sodium
transporters involved in the single effect—NKCC2 and the
a1 subunit of Na,K-ATPase—and the thiazide-sensitive NaCl
cotransporter (NCC). We decided to examine these trans-
porters because we had found that they had been down-
regulated in hypokalemia9 and after long-term treatment
with cyclosporin10 in association with reduced tonicity/
salinity of the renal medulla. In those animals treated with
12 mg furosemide/day, expression of these transporters did
not change except for a 2.8-fold increase in NKCC2 in the
cortex on day 1 (Figure 4). On the other hand, in those
animals treated with 40 mg furosemide/day, expression of
NKCC2 and the a1 subunit of Na,K-ATPase in the outer
medulla was dramatically reduced on both day 1 and day 5.
Expression of NCC did not change on day 1 but dropped by
B60% on day 5. We suspect that the enormous increase the
urine flow (223 vs 129 ml/day, see above) played a role in the
downregulation of sodium transporters (see Discussion).
Despite the large increase in urine flow and considerable
downregulation of sodium transporters, the decrease in
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Figure 2 | Effects of water diuresis and furosemide on
expression of TonEBP in the inner medulla. Rats were allowed
free access to water (euhydrated) or 3% sucrose (water loaded) for
3 days, or administered with furosemide for 1 or 5 days, as
described in Figure 1. Inner medullae were immunoblotted for
TonEBP. Protein loading was equalized based on the intensity of
Coomassie staining. Positions of size marker are shown at right.
Relative abundance is shown below each panel in mean±s.e.m.
@Po0.01 and *Po0.05 compared to 0 mg/day.
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sodium concentration of IMTW was small indicating that
12 mg furosemide/day was nearly as effective as 40 mg
furosemide/day in lowering the renal medullary tonicity.
In correlation with the decreased tonicity of the medullary
interstitium, as indicated by reduced sodium concentration
of IMTW, TonEBP expression in the inner medulla (bottom
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Figure 3 | Effects of water diuresis or 40 mg furosemide/day on expression of HSP70 and AR in the inner medulla. Top: protein and
mRNA for HSP70 and AR. Immunoblots were equally loaded based on the intensity of Coomassie staining. Likewise, Northern blots were equally
loaded based on the intensity of ethidium bromide staining of rRNA bands. The band intensity in the water loaded group relative to euhydrated
group, or the furosemide group relative to vehicle group is shown at right in Mean±SEM. *Po0.05 compared to euhydrated and @Po0.01
compared to vehicle. Bottom: Light micrographs of 50-mm-thick sections illustrating immunostaining for HSP70 (a–c) and AR (d–i) from inner
medullae of animals administered with vehicle (a, d, g) or 40 mg/day of furosemide for 1 day (b, e, h) or 5 days (c, f, i). ATL, ascending thin limb.
Arrow and arrowheads denote decreased immunoreactivity of HSP70 and AR in ATL and IMCD, respectively. Magnification:  528.
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panel in Figure 2) and the outer medulla (not shown) was
significantly reduced on day 1 and day 5. On the other hand,
TonEBP expression was not affected in the cortex (not
shown). Although the abundance of TonEBP mRNA
decreased by 33% in the outer medulla and 26% in the
inner medulla (Po0.05 for both) on day 1 in those animals
administered with 40 mg furosemide/day, the abundance
returned to normal on day 5 (not shown). Thus, both
reduced mRNA expression and posttranscriptional mechan-
ism were involved in the downregulation of TonEBP.
Immunohistological examinations revealed cytoplasmic shift
of TonEBP in the descending thin limb in addition to down
regulation of TonEBP in all areas of the medulla (Figure 5).
As expected, transcriptional activity of TonEBP as measured
by the abundance of AR and HSP70 mRNA was dramatically
reduced in the inner medulla (Figure 3). Protein abundance
of AR and HSP70 decreased slowly reaching significant levels
on day 5 most likely due to a very slow turnover of the
proteins.13 Abundance of SMIT mRNA also decreased
significantly in the outer and inner medullary regions on
day 1 and day 5 (data not shown). Taken together, these data
demonstrate that the expression and activity of TonEBP in
the renal medulla are reduced in association with reduced
interstitial tonicity in the animals administered with
furosemide.
DISCUSSION
In this study, two forms of diuresis—water diuresis induced
by excessive water intake, and another induced by the loop
diuretic furosemide—are examined for their effects on renal
expression of TonEBP. Even though the urine osmolality is
much lower—less than half—in water diuresis, estimated
osmolality and sodium concentration of the inner medullary
tissue water are lower in the furosemide-induced diuresis. As
sodium is predominantly localized in the extracellular
space,11 the data indicate that the interstitial tonicity of the
inner medulla is reduced in response to the loop diuretic but
not water diuresis. This correlates with the abundance of
TonEBP providing direct evidence that the interstitial tonicity
stimulates TonEBP expression in the inner medulla.
Recently we reported downregulation of TonEBP in the
renal medulla in two different models of diuresis due to
defective urinary concentration—hypokalemia9 and the
nephropathy induced by long-term treatment with cyclo-
sporin A.10 Both models are associated with downregulation
of the sodium transporters involved in the single effect—
NKCC2 and the a1 subunit of Na,K-ATPase—in the renal
medulla suggesting that reduced interstitial tonicity is
responsible for the reduced expression of TonEBP. Thus,
under normal conditions, the sodium transporters seem to
function upstream of TonEBP by producing local hyperto-
nicity. We sought to explore this idea further. Because of
complications from morphological and pathological changes
Table 1 | Analyses of rats administered with vehicle or
furosemide (40 mg/day) for day 1 or day 5
Day 1 Day 5
Vehicle Furosemide Vehicle Furosemide
Body weight (g) 226±3 207±4* 249±2 210±2@
creatinine (mg/100 ml) 0.53±0.03 0.80±0.07* 0.55±0.03 0.65±0.05
BUN (mg/100 ml) 18.8±2.1 32.0±3.1* 14.5±1.0 21.0±3.2
Albumin (g/100 ml) 2.7±0.0 3.2±0.1@ 2.7±0.1 2.8±0.2
Vasopressin (pg/ml) 43±20 364±96* 145±58 491±102*
Aldosterone (pM) 931±117 5197±1119@ 1013±212 2898±336@
Na+ (mEq/l) 144±1 144±1 146±4 142±3
K+ (mEq/l) 5.4±0.2 4.3±0.3* 4.9±0.4 5.1±0.2
Ca++ (mg/100 ml) 10.2±0.3 10.9±0.3 10.4±0.2 10.8±0.4
Cl (mEq/l) 104±1 89±3@ 104±3 92±6
HCO3
 (mEq/l) 26.8±0.9 36.8±1.1@ 22.2±0.6 34.7±1.2@
pH 7.44±0.04 7.52±0.02 7.43±0.02 7.49±0.06
Body weight and plasma samples were analyzed. Mean±s.e.m., n=4. Compared to
vehicle, *Po0.05, @Po0.01.
NKCC2 in CO
Day 1
Day 5
Day 1
Day 5
Day 1
Day 5
Day 1
Day 5
100 ±8.6 92 ± 5.8 122 ±12
0 mg/day 12 mg/day 40 mg/day
100 ± 11 105 ± 19 20 ± 16@
 100 ± 9.4 84 ± 11 50 ± 6.0@
110 ± 7.8100 ± 8.9 53 ± 4.8@
100 ± 16 116 ± 15 81 ± 20
150
150
150
150
150
150
150
150
100 ± 25 280 ± 27@ 240 ± 53*
100 ± 25 37 ± 13*56 ± 12*
76 ± 23100 ± 21 41 ± 20*
NKCC2 in OM
NCC in CO
Na,K-aTPase-1 in OM
Furosemide
Figure 4 | Effects of furosemide on renal expression of sodium
transporters. Rats were administered with 0, 12, or 40 mg
furosemide/day as described in Figure 1. Kidneys were obtained
at the end of day 1 and day 5, and extracts from cortices (CO) and
outer medullae (OM) were immunoblotted for NKCC2, NCC, and
the a1 subunit of Na,K-ATPase. Protein loading was equalized
based on the intensity of Coomassie staining. Relative abundance
is shown below each panel in mean±s.e.m. *Po0.05 and
@Po0.01 compared to 0 mg/day.
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such as interstitial fibrosis we did not analyze the inner
medullae in the cyclosporin-induced nephropathy. On the
other hand, we did analyze the inner medullae of hypoka-
lemic rats and found that sodium concentration in the inner
medullary water was reduced (142±5 vs 156±3 mM,
Po0.05; unpublished data) in agreement with a previous
report which used electron microprobe analysis.16 It is
possible that we may have underestimated the decreased in
sodium concentration because the inner medullae of
hypokalemic rats displayed hypertrophy, increased content
of renal blood cells, and reduced water content9 (not shown).
These observations further support the view that the
interstitial tonicity created by the sodium transporters
NKCC2 and the Na,K-ATPase stimulates expression of
TonEBP in the renal medulla.
Our data (Figure 4) show dramatic changes in the
expression of the renal sodium transporters in response to
furosemide. Although NCC expression was reported to be
elevated in response to the furosemide 17 or unchanged,18 we
found that NCC expression decreased on day 5. NKCC2
expression was reported to be elevated in the outer medulla
in response to furosemide,18 but we found it to be
dramatically reduced. Although differences in the dosage
and the length of treatment might explain the discrepant
observations, examination of the data in Figure 4 shows that
changes in the expression of renal sodium transporters are
more complex. First, expression of the Na,K-ATPase is
reduced in addition to changes in the NCC and NKCC2
expression. Second, the changes are dependent on the
location, that is, cortex vs medulla, and the dose and length
of furosemide administration. Although NKCC2 expression
is enhanced by furosemide in the cortex, it is reduced in the
outer medulla. In the cortex, the elevated expression of
NKCC2 is normalized after 5 days of furosemide treatment.
In the outer medulla, expression of NKCC2 and the Na,K-
ATPase is reduced dramatically in response to 40 mg/day of
furosemide but unaffected in response to 12 mg/day. The
downregulation of NKCC2 was unexpected because vaso-
pressin (Table 1) was elevated and it was likely that
angiotensin II was also elevated due to volume contraction
leading to higher levels of aldosterone (Table 1). Both
vasopressin19 and angiotensin II20 enhance the expression of
NKCC2. Likewise, the reduced expression of NCC (Figure 4)
despite elevated aldosterone (Table 1) was unexpected
because the mineralocorticoid pathway was known to
promote the NCC expression.21–23 As the reduced expression
was observed only in response to the higher dose of
furosemide, we speculate that the very high urine flow
might have interfered with the stimulatory action of the
hormones.
In the kidney-derived MDCK cells, induction of TonEBP
in response to hypertonicity is due to increased biosynthesis
pari passu with increase mRNA abundance.24 Stabilization of
mRNA contributes to the increased mRNA abundance,25
whereas the role of transcription is not known. In this study,
we find that both mRNA-dependent (associated with
decreased mRNA abundance) and mRNA-independent
(posttranscriptional) mechanisms are involved in the down-
regulation of TonEBP in response to furosemide. Posttran-
scriptional regulation of TonEBP is also reported in the brain.
In response to systemic hypernatremia, TonEBP abundance
in the nuclei of neurons increases rapidly26,27 without
changes in the mRNA abundance28 most likely due to
intracellular trafficking. Thus, posttranscriptional mechan-
Figure 5 | Light micrographs of 50-lm thick sections from outer medullae (a–c) and inner medullae (d–f) of animals infused with
vehicle (a, d) or 40 mg furosemide/day for 1day (b, e) or 5 days (c, f) illustrating immunostaining for TonEBP. DTL, descending
thin limb. Arrow heads denote cytoplasmic shift of TonEBP in DTL. Asterisk and arrows denote decreases in nuclear TonEBP in IMCD.
Original magnification:  350.
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isms are involved in the regulation of TonEBP expression in
the brain and the kidney.
In sum, the data presented here show that the tonicity of
the renal medullary interstitium is regulated independently of
the urine osmolality when water diuresis is compared with
furosemide-induced diuresis. More importantly, the data
provide direct evidence that TonEBP expression in the renal
medulla is driven by the interstitial tonicity. As the activity of
NKCC2 is required for the postnatal maturation of the renal
medulla,29 the hypertonicity-stimulated TonEBP is likely to
play a critical role in the medullary development as well as
the cellular protection from the stress of hyperosmolality and
the urinary concentration.
MATERIALS AND METHODS
Animal studies
Male Sprague–Dawley rats weighing 180 g (Harlan Sprague Dawley
Inc., Indianapolis, IN, USA) were acclimated to metabolic cages in a
temperature- and light-controlled room for 3 days. All the
procedures had been approved by the Institutional Animal Care
and Use Committee. For water loading, the animals were provided
with 3% sucrose in lieu of drinking water for 3 days. Intake of water
or the sucrose solution, urine output, and body weight were
monitored every 24 h.
For treatment with furosemide, each animal was anesthetized
with Ketamine and Xylazine, and an ALZET osmotic pump (Model
2ML1; Durect Corporation, Cupertino, CA, USA) containing
vehicle (50% dimethyl sulfoxide, pH 7) or furosemide was
implanted subcutaneously on the back between the scapulae. The
osmotic pump released 0, 12, or 40 mg furosemide/day for 5 days as
described previously.17 The animals were allowed free access to food,
water, and electrolyte solution containing 0.8% NaCl and 0.1% KCl.
Intake of water and electrolyte solution, urine output, and body
weight were monitored every 24 h. After day 1 or day 5, the animals
were killed by pentobarbital overdose and blood was collected from
the heart via syringe and needle.
For gas analysis, blood samples were collected in heparinized
microtubes and injected into ABL555 pH/blood gas analyzer
(Radiometer Nederland, Copenhagen, Denmark) to measure pCO2
and pH. Osmolality was measured by a vapor pressure osmometer
(Wescor, Logan, UT, USA), and plasma chemistries including
vasopressin and aldosterone were analyzed by a commercial service
(IDEXX lab, Sacramento, CA, USA).
Analyses of water and solutes of the inner medulla
Water and solutes of the inner medullae were analyzed from freshly
prepared tissues as described.30 Kidneys were rapidly removed and the
entire inner medullae were excised. Each inner medulla was squeezed
and blotted on a filter paper to remove urine. It was cut into four
pieces and weighed. The entire procedure for dissection and weighing
was less than 2 min per kidney. The tissues were dried overnight at 601
and weighed to estimate water content. To each tube 40ml of water was
added, which was then capped and heated for 3 min at 901 followed by
a storage at 41 for 24 h. The tubes were centrifuged and the
supernatants were collected for solute analyses. Osmolality of the
supernatant was measured as described above, and estimated tissue
osmolality was calculated from the total osmoles of the supernatant
and the volume tissue water. Likewise, sodium and potassium from
the supernatant were measured by flame photometry (Cole-Parmer,
Vernon Hills, IL, USA) and their tissue concentrations were calculated.
Immunoblot analyses
The kidneys were retrograde perfused via the abdominal aorta with
ice-cold phosphate-buffered saline for 15 s to remove the blood.
Cortex, outer medulla, and inner medulla were rapidly dissected
from each kidney on glass plates kept ice-cold. Freshly isolated
tissues were homogenized for 20 s in hot (80 1C) lysis buffer (1%
SDS, 1 mM sodium orthovanadate, 10 mM Tris-HCl, pH 7.5) using
Polytron (Brinkmann, Luzern, Switzerland) at full speed to
minimize the proteolysis of TonEBP. The homogenates were cleared
by centrifugation and separated on standard SDS gel electrophoresis
and blotted. Immunoblotting was performed as described previously
using the same antibodies9,10 except that HSP70 antibody (Stress-
gen, Victoria, British Columbia, Canada) was used in 1:2000
dilution. The blots were visualized with enhanced chemilumines-
cence and quantified by analyzing scanned images using Quantity
One (Bio-Rad, Hercules, CA, USA).
Isolation and analyses of RNA
RNA was extracted from cortex, outer medulla, and inner medulla
using TriZOL (Invitrogen, Carlsbad, CA, USA). Ribonuclease
protection assays for TonEBP and SMIT mRNA were performed as
described.10 For northern analysis, 3 mg RNA from each sample was
size-fractionated on an agarose gel containing 2.2 M formaldehyde
and transferred to a nitrocellulose membrane. Membranes were
hybridized overnight with 32P-labeled cDNA probes for HSP70
(corresponding to nucleotides 274 to 2691 of NCBI accession
M11717) or AR (NCBI accession J05474). Hybridizing bands were
visualized and quantified using a phosphorimager (Bio-Rad).
Immunohistochemistry
The kidneys were preserved by perfusion with periodatelysine-
paraformaldehyde solution for 4 min. They were then postfixed
overnight in the periodatelysine-paraformaldehyde solution after
they were cut into sagittal slices of 1–2 mm thickness. The fixed
tissues were process for preembedding immunolabeling for
TonEBP10 and AR31 as described previously. Immunolabeling of
HSP70 was performed the same way using the HSP70 antibody in
1:150 dilution.
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